ReviewInternational journal of molecular sciences2025
Exploring the Relevance of S100A8 and S100A9 Proteins in Preeclampsia: A Narrative Review.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interleukin-6, Proteinuria, and Arterial Stiffness in Preeclampsia: Distinct Inflammatory, Renal, and Vascular Associations.Biomedicines · 2026Article
- Neoplastic Disorders and Cardiovascular Comorbidities in Geriatric Patients: A Simple Association?Geriatrics (Basel, Switzerland) · 2026Review
- Activation of the S100A8/A9 Alarmin Amplifies Inflammatory Pathways in Equine Ascending Placentitis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a common pregnancy complication that may threaten the health of pregnant women and their fetuses. Intrauterine growth restriction is the most serious complication in fetal development observed in preeclampsia. In their later years, women with preeclampsia are at risk of cardiovascular disease. The use of multiple biomarkers can usually improve diagnostic performance. Currently, S100A8 and S100A9 are gaining increased attention as inflammatory markers of preeclampsia. Our review aims to present an integrated view of the potential role of S100A8/A9 in the physiopathology of preeclampsia. We also explored the potential role as biomarker or in targeted treatment. At the moment, there is no efficient treatment for PE other than birth. Understanding the pathological mechanisms and the importance of calprotectin can shape a new strategy for large-scale approaches to change diagnostic and therapeutic management. The value of the calcium binding proteins S100A8/A9 as a potential prognostic biomarker in placental disfunctions based on malperfusion has not yet been investigated. Encouraging results have been obtained in experimental and clinical interventional studies with S100A8/A9 blockers as a form of therapeutic management for autoimmune disease and cancer. It may also be limited because of safety issues for the fetus. However, future investigations can emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.